期刊文献+

一种gamma-delta T细胞体外扩增体系的研制 被引量:1

Development of a Gamma-Delta T Cell Amplification System in Vitro
下载PDF
导出
摘要 目的建立人单个核细胞培养的体外扩增gamma-delta T细胞体系,为肿瘤免疫细胞治疗奠定基础。方法采集体检健康人外周血,分离出单个核细胞,接种于含IL-2、唑来膦酸、 IL-18以及牻牛儿基牻牛儿基焦磷酸(GGPP)的体系中。根据加入激活剂种类的不同组合分为五个组,包括A组:唑来膦酸+IL-2; B组:唑来膦酸+IL-2+IL-18; C组:唑来膦酸+IL-2+GGPP; D组:唑来膦酸+IL-2+IL-18+GGPP; E组:不添加任何细胞因子作为激活剂。培养1周后,流式细胞术检测各组gamma-delta T细胞的纯度、颗粒酶B、穿孔素及CD56的阳性比例。以K562细胞为靶细胞, MTT实验观察细胞的体外杀伤活性。结果经过各组合细胞因子诱导7 d后, gamma-delta T细胞纯度均大于70%,细胞因子刺激组各组间gamma-delta T细胞纯度以及扩增倍数无显著差异(P>0.05)。经细胞因子刺激组的gamma-delta T细胞的颗粒酶B、细胞穿孔素以及CD56表达阳性率均显著高于E组,差异具有统计学意义(P <0.05)。经体外细胞因子处理后, gamma-delta T细胞不仅增殖数目与速度大大增加,而且一些具有杀伤作用的物质(颗粒酶B、细胞穿孔素与CD56)也大大增加,说明在细胞因子的参与下体外扩增对于肿瘤细胞的杀伤活性更强,杀伤效果更好。结论唑来膦酸、 IL-2、 IL-18、 GGPP可作为gamma-delta T细胞体外扩增体系中的重要组成部分,能够显著增强gamma-delta T细胞的毒活性,有效增强肿瘤细胞的杀伤活性。 Objective To establish a human mononuclear cell culture system to amplify gamma-delta T cells in vitro and to lay a foundation for tumor immunotherapy. Methods Peripheral blood samples from healthy individuals were collected and mononuclear cells were isolated. Inoculated with IL-2, Zoledronate acid, IL-18 and geranylgeranyl pyrophosphate (GGPP), they were divided into five groups according to different combinations of activators. Group A: Zoledronic acid + IL-2; group B: Zoledronic acid + IL-2 + IL-18; group C: Zoledronic acid + IL-2 + GGPP; group D: Zoledronic acid + IL-2 + IL-18 + GGPP; group E: no cytokine was added as an activator. The purity, granzyme B, perforin and positive proportion of CD56 of gamma-delta T cells in each group was detected by flow cytometry after l week's culture. K562 cells were used as target cells to observe the cytotoxicity of K562 cells in vitro. Results After 7 days of induction by various combination of cytokines, the purity ofCD56 T cells was higher than 70%, and there was no significant difference in the purity and amplification of gamma-delta T cells among the cytokine stimulation groups (P〉0.05). The granzyme B, perforin and positive proportion of CD56 of gamma-delta T cells in stimulation groups were significantly higher than those in group E, and the differences were statistically significant (P〈0.05). After in vitro cytokine treatment, T cell proliferation and the number of gamma-delta increased greatly, and some with the killing effects of substances (granzyme B, perforin and CD56 cells) also increased significantly, indicated that the in vitro amplification with the participation of cytokines had stronger killing activity against tumor cells and better killing effect. Conclusions Zoledronic acid, IL-2, IL-18 and GGPP can be used as important components of gamma-delta T cell expansion system in vitro, which can significantly enhance the toxic activity of gamma-delta T cells, and effectively enhance the killing activity of tumor cells.
作者 吴振勇 黄彩凤 陈晶砺 朱海勇 毕晓云 吴波 区绮云 WU Zhenyong;HUANG Caifeng;CHEN Jingli;ZHU Haiyong;BI Xiaoyun;WU Bo;OU Qiyun(Guangzhou Development District Hospital,Guangzhou 510730,China;Guangdong Jiangmen Chinese Medicine College,Jiangmen 529000,China)
出处 《临床医学工程》 2018年第10期1301-1303,共3页 Clinical Medicine & Engineering
基金 2016年江门市第五批科技计划项目(编号:1)
关键词 Gamma-delta T细胞 体外扩增 肿瘤过继免疫 Gamma-delta T cells In vitro expansion Adoptive immunity of tumor
  • 相关文献

参考文献2

二级参考文献10

  • 1Bubenik J.Tumour MHC class Ⅰ downregulation and immunotherapy[J].Oncol Rep,2003,10(6):2005-2008.
  • 2Mariani S,Muraro M,Pantaleoni F,et al.Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma[J].Leukemia,2005,19(4):664-670.
  • 3Lozupone F,Pende D,Burgio VL,et al.Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice[J].Cancer Res,2004,64(1):378-385.
  • 4Takeshi Y,Kiyoshi S,Eishi A,et al.Intravesical administration of γδT cells successfully prevents the growth of bladder cancer in the murine model[J].Cancer Immunol Immunother,2009,58(4):493-502.
  • 5Franeoise B,Florian C,Olivier T,et al.Vγ9Vδ2 T cell-mediated recognition of human solid tumors.Potential for immunotherapy of hepatocellular and colorectal carcinomas[J].Cancer Immunol Immunother,2008,57(4):531-539.
  • 6Bacei G,Brieeoli A,Ferrari S,et al.Neoadjuvant chemotherapy for osteosarcoma of the extremity.Long-term results of the Rizzoli's 4th protocol[J].Eur J Cancer,2001,37(16):2030-2039.
  • 7陈复兴,刘军权,冯霞,张娟,张颂.一种体外扩增人γδΤ细胞的新方法[J].细胞与分子免疫学杂志,2007,23(7):662-664. 被引量:31
  • 8李静,何维,胡愉.正常人 TCRγδ细胞系的建立及功能研究[J].上海免疫学杂志,1999,19(4):199-202. 被引量:8
  • 9Jean-Jacques Fournie,Helene Sicard,Mary Poupot,Christine Bezombes,Amandine Blanc,Franqois-Romagne,Loic Ysebaert,Guy Laurent.What lessons can be learned from y T cell-based cancer immunotherapy trials?[J].Cellular & Molecular Immunology,2013,10(1):35-41. 被引量:7
  • 10陈勇,吕合作,胡建国,李柏青.刺激人γδT细胞增殖的结核杆菌多肽抗原的生物学特性分析[J].细胞与分子免疫学杂志,2003,19(2):121-123. 被引量:10

共引文献7

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部